Single‑nucleotide polymorphisms in the promoter of the gene encoding for C‑reactive protein associated with acute coronary syndrome.

C-reactive protein acute coronary syndrome polymorphisms quantitative PCR risk

Journal

Biomedical reports
ISSN: 2049-9442
Titre abrégé: Biomed Rep
Pays: England
ID NLM: 101613227

Informations de publication

Date de publication:
Nov 2024
Historique:
received: 24 10 2023
accepted: 26 07 2024
medline: 9 9 2024
pubmed: 9 9 2024
entrez: 9 9 2024
Statut: epublish

Résumé

Acute coronary syndrome (ACS) is a leading cause of mortality worldwide. Several studies have shown that certain single nucleotide polymorphisms (SNPs) are linked to the development of ACS. In particular, C-reactive protein (CRP) has emerged as an important predictive biomarker for cardiovascular disease. The current study aimed to investigate four polymorphisms of the CRP gene as possible biomarkers for ACS in a sample of 252 individuals (114 patients with ACS and 138 healthy controls) from Southeastern Mexico. Multivariate analysis adjusted for clinical variables showed that the polymorphism 3872CT for the genotype CC/CT [adjusted Odds Ratio (AdOR)=3.78; 95% Confidence Interval (CI): 1.11-12.92; P=0.034] and the genotype GG/GC of the polymorphisms 2667CG (AdOR=4.82; 95% CI: 1.69-13.72; P=0.02) were associated with ACS. However, the polymorphisms 3006AC genotype AA/AC and 5237GA genotype GG/GC were not found to be associated in the multivariate analysis with ACS (P>0.05). These results suggested that 3872CC/CT and 2667CC/CG polymorphism of the CRP gene plays a significant role in the development of ACS.

Identifiants

pubmed: 39247423
doi: 10.3892/br.2024.1838
pii: BR-21-5-01838
pmc: PMC11375626
doi:

Types de publication

Journal Article

Langues

eng

Pagination

150

Informations de copyright

Copyright: © 2024 Lopez-Roblero et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Auteurs

Alexander Lopez-Roblero (A)

Diagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.

Eleazar Serrano-Guzmán (E)

Diagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.
Regional High Specialty Hospital, Tapachula, Chiapas 30700, México.

Rocío Stephania Guerrero-Báez (RS)

Diagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.

Iván Delgado-Enciso (I)

Cancerology State Institute, Colima State Health Services, Colima 28085, México.
School of Medicine, University of Colima, Colima 28040, México.

Saúl Gómez-Manzo (S)

Genetic Biochemistry Laboratory, National Institute of Pediatrics, Ministry of Health, México City 04530, México.

Javier Aguilar-Fuentes (J)

Faculty of Agricultural Sciences, Autonomous University of Chiapas, Huehuetán, Chiapas 30660, México.

Vivían Ovando-Garay (V)

Faculty of Medicine, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.

Beatriz Hernández-Ochoa (B)

Immunochemistry Laboratory, Children's Hospital of México Federico Gómez, Ministry of Health, México City 06720, México.

Iliana Concepción Quezada-Cruz (IC)

Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.

Noe Lopez-Lopez (N)

Diagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.

Luis Miguel Canseco-Ávila (LM)

Diagnostic and Molecular Biomedicine Laboratory, Faculty of Chemistry Sciences, Campus IV, Autonomous University of Chiapas, Tapachula, Chiapas 30700, México.

Classifications MeSH